Parkinson's disease and somatosensory evoked potentials

Apomorphine-induced transient potentiation of frontal components

P. M. Rossini, R. Traversa, P. Boccasena, G. Martino, F. Passarelli, L. Pacifici, G. Bernardi, P. Stanzione

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

We recorded somatosensory evoked potentials (SEPs) to median nerve stimulation from parietal and frontal districts in 32 patients with Parkinson's disease by evaluating latency/amplitude characteristics of the parietal P14-N20-P25 and of the frontal P20-N30-P40 wave complexes before and 10, 20, 30, and 60 minutes after subcutaneous administration of apomorphine chloride. The frontal complex N30-P40 was smaller than normal in 17 patients in baseline recordings. Following apomorphine, the parietal responses did not significantly vary in amplitude, but the frontal complex showed a remarkable amplitude potentiation in 22 of 32 patients (68.7%, p <0.001), 19 of whom were also improving clinically. Amplitude potentiation was evident 10 minutes after apomorphine and faded away nearly in parallel with the end of its clinical efficacy. There were no SEP changes in three healthy controls after apomorphine.

Original languageEnglish
Pages (from-to)2495-2500
Number of pages6
JournalNeurology
Volume43
Issue number12
Publication statusPublished - Dec 1993

Fingerprint

Somatosensory Evoked Potentials
Apomorphine
Parkinson Disease
Median Nerve
Parietal
Parkinson's Disease
Evoked Potentials
adjuvant P40

ASJC Scopus subject areas

  • Neuroscience(all)
  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Rossini, P. M., Traversa, R., Boccasena, P., Martino, G., Passarelli, F., Pacifici, L., ... Stanzione, P. (1993). Parkinson's disease and somatosensory evoked potentials: Apomorphine-induced transient potentiation of frontal components. Neurology, 43(12), 2495-2500.

Parkinson's disease and somatosensory evoked potentials : Apomorphine-induced transient potentiation of frontal components. / Rossini, P. M.; Traversa, R.; Boccasena, P.; Martino, G.; Passarelli, F.; Pacifici, L.; Bernardi, G.; Stanzione, P.

In: Neurology, Vol. 43, No. 12, 12.1993, p. 2495-2500.

Research output: Contribution to journalArticle

Rossini, PM, Traversa, R, Boccasena, P, Martino, G, Passarelli, F, Pacifici, L, Bernardi, G & Stanzione, P 1993, 'Parkinson's disease and somatosensory evoked potentials: Apomorphine-induced transient potentiation of frontal components', Neurology, vol. 43, no. 12, pp. 2495-2500.
Rossini, P. M. ; Traversa, R. ; Boccasena, P. ; Martino, G. ; Passarelli, F. ; Pacifici, L. ; Bernardi, G. ; Stanzione, P. / Parkinson's disease and somatosensory evoked potentials : Apomorphine-induced transient potentiation of frontal components. In: Neurology. 1993 ; Vol. 43, No. 12. pp. 2495-2500.
@article{7d621facc1224dca9ea90d687b5ac23a,
title = "Parkinson's disease and somatosensory evoked potentials: Apomorphine-induced transient potentiation of frontal components",
abstract = "We recorded somatosensory evoked potentials (SEPs) to median nerve stimulation from parietal and frontal districts in 32 patients with Parkinson's disease by evaluating latency/amplitude characteristics of the parietal P14-N20-P25 and of the frontal P20-N30-P40 wave complexes before and 10, 20, 30, and 60 minutes after subcutaneous administration of apomorphine chloride. The frontal complex N30-P40 was smaller than normal in 17 patients in baseline recordings. Following apomorphine, the parietal responses did not significantly vary in amplitude, but the frontal complex showed a remarkable amplitude potentiation in 22 of 32 patients (68.7{\%}, p <0.001), 19 of whom were also improving clinically. Amplitude potentiation was evident 10 minutes after apomorphine and faded away nearly in parallel with the end of its clinical efficacy. There were no SEP changes in three healthy controls after apomorphine.",
author = "Rossini, {P. M.} and R. Traversa and P. Boccasena and G. Martino and F. Passarelli and L. Pacifici and G. Bernardi and P. Stanzione",
year = "1993",
month = "12",
language = "English",
volume = "43",
pages = "2495--2500",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Parkinson's disease and somatosensory evoked potentials

T2 - Apomorphine-induced transient potentiation of frontal components

AU - Rossini, P. M.

AU - Traversa, R.

AU - Boccasena, P.

AU - Martino, G.

AU - Passarelli, F.

AU - Pacifici, L.

AU - Bernardi, G.

AU - Stanzione, P.

PY - 1993/12

Y1 - 1993/12

N2 - We recorded somatosensory evoked potentials (SEPs) to median nerve stimulation from parietal and frontal districts in 32 patients with Parkinson's disease by evaluating latency/amplitude characteristics of the parietal P14-N20-P25 and of the frontal P20-N30-P40 wave complexes before and 10, 20, 30, and 60 minutes after subcutaneous administration of apomorphine chloride. The frontal complex N30-P40 was smaller than normal in 17 patients in baseline recordings. Following apomorphine, the parietal responses did not significantly vary in amplitude, but the frontal complex showed a remarkable amplitude potentiation in 22 of 32 patients (68.7%, p <0.001), 19 of whom were also improving clinically. Amplitude potentiation was evident 10 minutes after apomorphine and faded away nearly in parallel with the end of its clinical efficacy. There were no SEP changes in three healthy controls after apomorphine.

AB - We recorded somatosensory evoked potentials (SEPs) to median nerve stimulation from parietal and frontal districts in 32 patients with Parkinson's disease by evaluating latency/amplitude characteristics of the parietal P14-N20-P25 and of the frontal P20-N30-P40 wave complexes before and 10, 20, 30, and 60 minutes after subcutaneous administration of apomorphine chloride. The frontal complex N30-P40 was smaller than normal in 17 patients in baseline recordings. Following apomorphine, the parietal responses did not significantly vary in amplitude, but the frontal complex showed a remarkable amplitude potentiation in 22 of 32 patients (68.7%, p <0.001), 19 of whom were also improving clinically. Amplitude potentiation was evident 10 minutes after apomorphine and faded away nearly in parallel with the end of its clinical efficacy. There were no SEP changes in three healthy controls after apomorphine.

UR - http://www.scopus.com/inward/record.url?scp=0027722282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027722282&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 2495

EP - 2500

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -